Gmed stock price forecast year-to-date performance has GMED up

Year-to-date performance has GMED up 14%, outperforming the S&P 500 Healthcare Index. The GMED stock price forecast incorporates this relative strength as a basis for sustained momentum in H2. Are you a shareholder? GMED’s optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven’t considered today, such as the track record of its management team. Have these factors changed since the last time you looked at GMED? Will you have enough conviction to buy should the price fluctuate below the industry PE ratio? Based on the Q3 performance and the outlook for the rest of the year, management raised 2024 revenue guidance to between $2.49 billion and $2.50 billion, up from the previous range of $2.47 billion to $2.49 billion. Also, the full-year forecast for adjusted EPS was boosted to $2.90-$3.00 from $2.80-$2.90. Current market sentiment around the GMED stock price forecast indicates a short-term consolidation phase as shares hover near $61.